|
|
| |
| Most Discussed Stocks |
 |
|
|
|
| |
|
News |
| |
|
WILL THE FDA GIVE THE GREEN LIGHT T.... |
10/06/2008 |
|
Has the time come for Provenge, the prostate cancer vaccine developed by Dendreon, to be given marketing approval so it can save condemned metastatic prostate cancer patients’ lives? |
| |
|
PROGENICS: THE HIV DRUG LOOKS PROMI.... |
10/02/2008 |
|
|
| |
|
WE WILL BE ALL RIGHT |
09/25/2008 |
|
We gave you Sequenom and many other winners. Prohost will continue to do the same, hopefully without as much struggling against the greed of those who took advantage of the market deregulation to turn it into a vehicle for self-fulfillment of destructive prophesies at the expense of the serious investors.
We surely believe that America is capable of overcoming this crisis. Yet, our hope is in a reform that stops the greed that tarnished the market’s and America’s strong economy’s reputation.
We will be all right.
|
| |
|
SEQUENOM (SQNM): SUCCESS OF NON INV.... |
09/24/2008 |
|
The results are 100% without manipulation of the fetus and with a simple mother\'s blood test. |
| |
|
CYTRX COMPLETES ITS BUYOUT OF INNOV.... |
09/23/2008 |
|
Cytrx inherited the cancer drug tamibarotene, which has been approved in Japan for acute promyelocytic leukemia (APL). It also inherited three other drug candidates. Read about tamibarotene. Read also about the a stool test that shows successful results in diagnosing colorectal cancer. |
| |
|
|
| |
| |
| |
|
|
Stocks >> Stocks Details |
|
ACHN
|
| |
|
DRUG-RESISTANT HOSPITAL INFECTIONS |
|
|
|
ACHILLION PHARMACEUTICALS
|
| |
|
Achillion develops biopharmaceutical
treatments for infectious diseases. The pipeline includes HIV and
hepatitis C treatments, as well as antibacterial treatments for
drug-resistant hospital-based bacterial infections.
Pipeline:
Elvucitabine: The lead candidate in Phase
2 trials for the treatment of HIV patients who have become resistant to
existing antiviral drugs.
ACH-806: For chronic hepatitis C in collaboration with Gilead
Sciences
Web: www.achillion.com
|
| |
| |
| |
| |
| |
| |
|
|
|
|
